APPENDIX 2: David Hinde attendance note of Nuneaton meeting,
30 September 2003

Attendance Note

Meeting Tuesday 30th September 2003


H&B HQ in Nuneaton


Peter Aldis (Chair HFMA, MD H&B)
David Adams (Dir, HFMA)
Christopher Whitehouse (Consultant, HFMA)
Steve Ryan (MD, Bee Health)
Mike Abrahams (Chair, NAHS)
Ralph Pike (Dir, NAHS)
Andrew Lockley (Solicitor, Irwin Mitchell: Client NAHS)
David Hinde (Solicitor, Legal Dir, ANH)
Jeremy Arbib (Publicity Manager, ANH)
Dr Rob Verkerk (Exec Dir, ANH)

Key Points Discussed

Peter Aldis proposed CW as chair for the meeting given he had been somewhat less involved in the issues and was a political lobbyist, to which all agreed.

Right at the start of the meeting it was agreed that all parties had a similar objective, i.e. to mount one united legal challenge to FSD that industry in Europe and the US could get behind.

It was made clear that ANH was in a position to run on its own if it needed to, although it would welcome the broadest possible cooperation as this would make for an even stronger case in the courts.

MA indicated that what was envisaged was cooperation between the 3 organisations in bringing the case with each providing its own particular expertise;

NAHS       Technical input
ANH        Publicity and fund-raising (RV pointed out here that
           ANH can also provide fairly substantial technical inputs)
HFMA       Technical support, 'industry approval' and savings on
           costs (PA gave as an example meeting the costs of an
           economic expert witness to industry)

PA explained that whilst there had not been a vote at the recent HFMA Council Meeting to back an FSD challenge because of the "delicate circumstances", the matter was discussed at length and he was able to say that the HFMA" was supportive of becoming involved in an FSD challenge".

AL was asked to confirm exactly how much more money would be required to get an FSD judicial review application for leave into Court and for the substantive hearing of such an application (what was variously described as "Phase 1).

Page 12

Previous Page

IAHF Home Page